Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S.
Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11;10(8):728-737. doi: 10.1093/ehjcvp/pvae071.